Overview

Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Suramin may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining suramin with radiation therapy may be a more effective treatment for glioblastoma multiforme. PURPOSE: Phase II trial to study the effectiveness of suramin plus radiation therapy in treating patients who have newly diagnosed glioblastoma multiforme.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
National Cancer Institute (NCI)
Treatments:
Suramin
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed supratentorial glioblastoma multiforme No
prior intracranial or intratumoral hemorrhage

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life
expectancy: Greater than 2 months Hematopoietic: Absolute neutrophil count at least
1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL No history of a
bleeding disorder that would interfere with protocol therapy Hepatic: Bilirubin no greater
than 1.5 mg/dL Transaminases no greater than 4 times upper limit of normal Renal:
Creatinine no greater than 1.7 mg/dL Cardiovascular: No suspected disseminated
intravascular coagulation No history of venous thrombosis requiring coumadin Other: No
serious concurrent infection or other medical illness that would prevent compliance No
other malignancy within the past 5 years except curatively treated basal cell skin cancer
or carcinoma in situ of the cervix Not pregnant or nursing Negative pregnancy test Fertile
patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy or biologic agents
(e.g., immunotoxins, immunoconjugates, antisense, peptide receptor antagonists,
interferons, interleukins, lymphokine activated killer cells, tumor infiltrating
lymphocytes, or gene therapy) for brain tumor Chemotherapy: No prior chemotherapy for brain
tumor Endocrine therapy: No prior hormonal therapy for brain tumor Prior glucocorticoids
allowed Maintenance 5 day stable corticosteroid regimen required postsurgery Radiotherapy:
No prior radiotherapy for brain tumor Surgery: Prior surgery for brain tumor allowed if
recovered from the immediate post operative period